Isoray, Inc. (ISR) saw a push of 4.21% in aftermarket and stands at $0.4897. However, the last trading session concluded at $0.4699 with an increase of 1.89%.
First Quarter Fiscal 2022 Financial Results – Let’s see what happened?
ISR reported first-quarter results on 10th November 2021. The revenue increased by 8% to $2.56 million in the first quarter of fiscal 2022, compared to $2.38 million in the prior year’s similar period. In comparison to the first quarter of fiscal 2021, the company’s core prostate brachytherapy revenue climbed by 4%. Moreover, in the first quarter, total operational expenditures grew by 69 percent to $3.30 million, $1.96 million more than the previous year. Furthermore, the total research and development costs climbed by 125 percent. Lastly, the net loss was $2.24 million, compared to a net loss of $0.71 million in the corresponding prior-year period.
What’s up?
The outlook for the core prostate brachytherapy business, which increased year over year this quarter, is encouraging. As the research pipeline develops, ISR is taking crucial actions to support the organization’s scaling in preparation for future growth. The steps will be taken in both our core prostate brachytherapy market and sectors connected to difficult-to-treat malignancies.
Isoray’s Cesium-131 Recognition
On 28th September 2021, it was announced that in its newly revised consensus statement on the subject of low dose rate (LDR) prostate brachytherapy, the American Brachytherapy Society (ABS) has acknowledged Isoray’s Cesium-131. Cesium-131 seeds were not accessible as a treatment until 2004, hence long-term results from Cesium-131 prostate brachytherapy seeds have just recently been available. Lastly, ABS does not rate or recommend any particular treatment approach. Instead, it tries to focus on analyzing data and offering insight into studies around the use of brachytherapy in the treatment of metastatic and benign illnesses.
Fourth Quarter Results in 2021
ISR reported fourth-quarter results on 21st September 2021. Revenue increased 19 percent to $2.71 million in the fourth quarter of fiscal 2021. When compared to the fiscal fourth quarter of 2020, the Company’s core prostate brachytherapy revenue increased by 5%. Moreover, prostate brachytherapy accounted for 74 percent of overall revenue in the fourth quarter of fiscal 2021, down from 84 percent the year before.
The total operating expenditures climbed by 8% to $2.44 million, $2.26 million more than the prior year’s comparable period. In comparison to the previous year’s similar quarter, total research and development costs climbed by 45 percent. Furthermore, the sales and marketing costs were down 4%. When compared to the prior year’s comparable quarter, the decreases in sales and marketing expenditures drove the lower incentive compensation.
